Literature DB >> 30796681

Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006-2009 Study.

Jean-Médard Kankou1,2, Olivier Bouchaud1,3, Nathalie Lele1, Marguerite Guiguet4, Bruno Spire5,6,7, Maria Patrizia Carrieri5,6,7, Sophie Abgrall8,9,10.   

Abstract

In France, around 25% of the estimated number of people living with HIV are migrants, of whom three quarters are from sub-Saharan Africa (SSA). Our objective was to determine factors associated with virological rebound (VR) at the occasion of a transient stay to the country of origin. HIV-positive migrants from SSA participating to the ANRS-VIHVO adherence study between 2006 and 2009, on effective ART with controlled pre-travel HIV-1 plasma viral load (VL), were included. Outcome was VR, defined as VL ≥ 50 copies/ml at the post-travel visit during the week following the return to France. Among 237 persons (61.6% female, median age 41 years (IQR, 35-47), median time on ART 4.2 years (IQR, 2.2-7.1), 27 (11.4%) experienced VR. The main purpose of the travel was to visit family and median time spent abroad was 5.3 weeks (IQR, 4.1-8.8). The travel was extended longer than anticipated by at least 1 week in 42 individuals (17.7%). In multivariable logistic model, risk factors for VR were male sex [adjusted OR (aOR) 5.1; 95% CI 1.6-16.2)], no employment in France (aOR 2.0; 1.2-3.5), self-reported non-adherence during the trip (aOR 14.9; 4.9-45.9) and PI-containing regimen (aOR 4.6; 1.2-17.6). In another analysis not including self-reported adherence, traveling during Ramadan while respecting the fast (aOR 3.3; 1.2-9.6) and extension of the stay (aOR 3.0; 1.1-7.8) were associated with VR. Virological rebound was partly explained by structural barriers to adherence such as extension of the travel and inadequate management of Ramadan fasting. Individuals' journeys should be carefully planned with health care providers.

Entities:  

Keywords:  Antiretroviral therapy; HIV; Migrant; Sub-Saharan Africa; Travel; Virological rebound

Mesh:

Substances:

Year:  2019        PMID: 30796681     DOI: 10.1007/s10903-019-00864-y

Source DB:  PubMed          Journal:  J Immigr Minor Health        ISSN: 1557-1912


  25 in total

1.  Anti-retroviral therapy among HIV infected travelers to Hajj pilgrimage.

Authors:  Abdulrazaq G Habib; Murjanatu Abdulmumini; Mahmoud M Dalhat; Muhammad Hamza; Garba Iliyasu
Journal:  J Travel Med       Date:  2010 May-Jun       Impact factor: 8.490

2.  Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?

Authors:  Berta Pernas; Marta Grandal; Sonia Pertega; Angelina Cañizares; Ángeles Castro-Iglesias; Álvaro Mena; Iria Rodriguez-Osorio; Andrés Tabernilla; José D Pedreira; Eva Poveda
Journal:  J Antimicrob Chemother       Date:  2015-12-24       Impact factor: 5.790

3.  Do migrants overreport adherence to highly active antiretroviral therapy?: results from the French VESPA (ANRS-EN12) National Survey.

Authors:  Fabienne Marcellin; M Patrizia Carrieri; Patrick Peretti-Watel; Anne-Déborah Bouhnik; Yolande Obadia; France Lert; Bruno Spire
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

4.  Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression.

Authors:  Virginie Supervie; Lise Marty; Jean-Marc Lacombe; Rosemary Dray-Spira; Dominique Costagliola
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

5.  Comparative evaluation of adherence to antiretroviral therapy in sub-Saharan African native HIV-infected patients in France and Africa.

Authors:  Pierre Sellier; Philippe Clevenbergh; Liliana Ljubicic; Guy Simoneau; John Evans; Véronique Delcey; Myriam Diemer; Marc Bendenoun; Stéphane Mouly; Jean-François Bergmann
Journal:  Clin Infect Dis       Date:  2006-07-26       Impact factor: 9.079

6.  Characteristics of HIV infected individuals traveling abroad. Results from the +REDIVI Collaborative Network.

Authors:  Jose A Pérez-Molina; Angela Martinez-Perez; Nuria Serre; Begoña Treviño; José Manuel Ruiz-Giardín; Diego Torrús; Josune Goikoetxea; Esteban Martín Echevarría; Eduardo Malmierca; Gerardo Rojo; Eva Calabuig; Belén Gutierrez; Francesca Norman; Rogelio Lopez-Velez
Journal:  Enferm Infecc Microbiol Clin       Date:  2015-05-26       Impact factor: 1.731

7.  Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Authors:  Anna M Geretti; Colette Smith; Annette Haberl; Ana Garcia-Diaz; Gaia Nebbia; Margaret Johnson; Andrew Phillips; Schlomo Staszewski
Journal:  Antivir Ther       Date:  2008

8.  Visiting one's native country: the risks of nonadherence in HIV-infected sub-Saharan migrants--ANRS VIHVO study.

Authors:  Sophie Abgrall; Lionel Fugon; Nathalie Lélé; Estelle Carde; Michelle Bentata; Olivier Patey; Marie-Aude Khuong; Bruno Spire; Patrizia Carrieri; Olivier Bouchaud
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-05-22

9.  Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.

Authors:  Cynthia Firnhaber; Livio Azzoni; Andrea S Foulkes; Robert Gross; Xiangfan Yin; Desiree Van Amsterdam; Doreen Schulze; Deborah K Glencross; Wendy Stevens; Gillian Hunt; Lynn Morris; Lawrence Fox; Ian Sanne; Luis J Montaner
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

10.  Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.

Authors:  Marie-Anne Vandenhende; Suzanne Ingle; Margaret May; Geneviève Chene; Robert Zangerle; Ard Van Sighem; M John Gill; Carolynne Schwarze-Zander; Beatriz Hernandez-Novoa; Niels Obel; Ole Kirk; Sophie Abgrall; Jodie Guest; Hasina Samji; Antonella D'Arminio Monforte; Josep M Llibre; Colette Smith; Matthias Cavassini; Greer A Burkholder; Bryan Shepherd; Heidi M Crane; Jonathan Sterne; Philippe Morlat
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.